Ascletis Pharma Inc.

Investors

Announcement - Inside Information - Business Update on ASC10, an Oral Double Prodrug against COVID-19
2022-03-15
Announcement - Inside Information - Ascletis Announces Further Expansion of Ritonavir Oral Tablet Production Capacity to 530 Million Tablets Per Year
2022-03-13
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2022
2022-03-03
Notice of Board Meeting
2022-03-02
Announcement - Inside Information - Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Eight Additional European Countries
2022-03-01
Positive Profit Alert
2022-02-27
Voluntary Announcement - Shanghai Public Health Clinical Center Initiated Functional Cure Study of Anti-PD-L1 Antibody ASC22 (Envafolimab) in Combination with Chidamide in HIV-Infected Patients
2022-02-14
Announcement - Inside Information - Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Multiple European Countries
2022-02-13
Announcement - Inside Information - Ascletis Announces Positive Data of Oral Double Prodrug ASC10 and Its Antiviral Nucleoside Analog ASC10-A against Omicron Variant
2022-02-07
Voluntary Announcement - Ascletis Announces U.S. IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors
2022-02-06

3

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1